

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/M253B3B93F7EN.html>

Date: March 2020

Pages: 102

Price: US\$ 2,000.00 (Single User License)

ID: M253B3B93F7EN

Abstracts

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2020, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Marburg hemorrhagic fever is a rare, acute infectious which affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain and weight loss.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Marburgvirus

Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 18 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 4 and 2 molecules, respectively.

Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all

their major and minor projects.

The pipeline guide evaluates Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Overview

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Development

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Assessment

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Companies Involved in
Therapeutics Development

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drug Profiles

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Product Development

Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by ANP Technologies Inc, H1 2020

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by BioCryst Pharmaceuticals Inc, H1 2020

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Collaborations Pharmaceuticals Inc, H1 2020

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Eisai Co Ltd, H1 2020

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, H1 2020

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Emergex Vaccines Ltd, H1 2020

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Fab'entech SA, H1 2020

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects, H1 2020

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects, H1 2020 (Contd..1), H1 2020

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

ANP Technologies Inc

BioCryst Pharmaceuticals Inc

Collaborations Pharmaceuticals Inc

Eisai Co Ltd

Emergent BioSolutions Inc

Emergex Vaccines Ltd

Fab'entech SA

Flow Pharma Inc

Fox Chase Chemical Diversity Center Inc

GeoVax Labs Inc

Greffex Inc

IDBiologics Inc

Immunomodulation Inc

Integrated BioTherapeutics Inc

Intervir Therapeutics

Johnson & Johnson

Mapp Biopharmaceutical Inc

Phoenix Biotechnology Inc

Profectus BioSciences Inc

Rodos BioTarget GmbH

I would like to order

Product name: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/M253B3B93F7EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M253B3B93F7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970